GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial

2022 ◽  
Author(s):  
Wei-Ting Chen ◽  
Shi-Ming Lin ◽  
Wei-Chen Lee ◽  
Ting-Jung Wu ◽  
Chen-Chun Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Randomized Trial ◽  
Sorafenib Therapy

scholarly journals Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series

2021 ◽  
pp. 224-231
Author(s):  
Richard T. Lee ◽  
Peiying Yang ◽  
Asrar Alahmadi ◽  
Jennifer McQuade ◽  
Eric Yuan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Time ◽  
Injection Site Reaction ◽  
Case Series ◽  
Advanced Hepatocellular Carcinoma ◽  
Site Reaction ◽  
Advanced Hcc ◽  
Mistletoe Extract ◽  
Sorafenib Therapy ◽  
Mistletoe Extracts

Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of death from cancer worldwide, and for advanced HCC the prognosis is poor. Preliminary studies indicate mistletoe extracts may have anticancer activity for HCC. Methods: A prospective observational case series of advanced HCC patients that chose to take a mistletoe extract called viscum fraxini-2 (VF-2) alone for treatment. Time on treatment, imaging, and laboratory values were collected for descriptive analyses. Results: A total of 12 patients with advanced HCC enrolled onto the protocol, and 10 patients had data available for evaluation. The majority were male (10/12) with a median age of 64 (SD 11). Most patients had received sorafenib therapy (9/12) and had varying Child-Pugh classes (A-4, B-6, C-2). Treatment with VF-2 ranged from 1 to 36 weeks with a mean of 12.3 weeks (SD 12). Six patients received 8 weeks of treatment, and 3 patients received 12 or more weeks of treatment. For patients that received at least 4 weeks of treatment, the average AFP value stabilized during the first 4 weeks of treatment. Two patients experienced an AFP decrease of >30%, approximately 37 and 40% decreases at the nadir. One patient had stable disease of 9 months. Major side effects were fever, fatigue, rash, and local injection site reaction of swelling, redness, and tenderness. Conclusion: This case series of advanced HCC indicates that mistletoe extract VF-2 may have potential biological activity against HCC for selected patients. Research is needed to identify the active compound and predictive markers of response.

scholarly journals Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan

2014 ◽  
Vol 5 (7) ◽  
pp. 499-509 ◽  
Author(s):  
Hiroki Nishikawa ◽  
Haruhiko Takeda ◽  
Kaoru Tsuchiya ◽  
Kouji Joko ◽  
Chikara Ogawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Outcome ◽  
Multicenter Study ◽  
Aged Patients ◽  
Sorafenib Therapy

scholarly journals Value of α‑fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma

2018 ◽  
Author(s):  
Ana Plano S�nchez ◽  
Luc�a Velasco Roces ◽  
Isabel Zapico Garc�a ◽  
Eva L�zaro L�pez ◽  
Miguel Calleja Hernandez ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
Early Biomarker

Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia

2020 ◽  
Vol 32 (10) ◽  
pp. 1407-1408
Author(s):  
Elizabeth S. Aby ◽  
Amir Sultan ◽  
Abate Bane ◽  
Zerihun Wondifraw ◽  
Jose D. Debes
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Single Center ◽  
Sorafenib Therapy

Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.

1984 ◽  
Vol 2 (6) ◽  
pp. 581-584 ◽  
Author(s):  
G Falkson ◽  
J M MacIntyre ◽  
A J Schutt ◽  
B Coetzer ◽  
L A Johnson ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Randomized Trial ◽  
South African ◽  
Median Survival ◽  
Objective Response ◽  
Eastern Cooperative Oncology Group ◽  
Prospective Randomized Trial ◽  
Severe Toxicity ◽  
Oncology Group ◽  
Survival Times

Sixty-one of 76 patients entered on a prospective randomized trial of neocarzinostatin ( NCZ ) versus m-AMSA or doxorubicin were eligible for analysis. Among these 61 patients at least one episode of severe toxicity was documented in 39% of patients on NCZ and 58% on m-AMSA. Fifty-one of the 61 patients were previously untreated with chemotherapy. Among these 51 patients objective response was documented in two of 25 patients treated with NCZ , none of 17 treated with m-AMSA, and one of nine treated with doxorubicin. Among previously untreated North American and European (NA/E) patients the median survival times were: NCZ 11 weeks and m-AMSA 12 weeks. The data on South African (SA) patients with similar entrance criteria entered on earlier Eastern Cooperative Oncology Group trials were analyzed with that from the randomized trial and show that for SA patients the median survival times were: NCZ , 11 weeks (31 patients); m-AMSA, 13 weeks (33 patients); and doxorubicin, 15 weeks (29 patients).

Sign in / Sign up

Export Citation Format

Share Document